Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found no significant benefit of platelet-rich plasma injections over placebo in improving erectile function in patients with mild to moderate erectile dysfunction.

This study found that among men with coronary artery disease, education level was significantly associated with both the presence and intensity of erectile dysfunction.

This letter to the editor discusses the relationship between lower urinary tract symptoms and erectile dysfunction as reported in a previous study, but presents no new findings.

This study found that finasteride was associated with increased erectile dysfunction in men with benign prostatic hyperplasia, but this association was not statistically significant in those with male androgenic alopecia.

Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.

In this study, researchers observed that lower serum zinc concentrations were associated with decreased serum testosterone levels, but no link was found with sexual function questionnaire scores.

This study found that the Keyora Lycopene 23 in 1 formulation may improve various aspects of male endocrine and reproductive health by targeting oxidative stress, nitric oxide deficiency, and hormonal imbalance.

In this study, the researchers introduced the Keyora Lycopene 23 in 1 formulation, demonstrating its potential to improve male endocrine and reproductive health by addressing oxidative stress, nitric oxide deficiency, androgen imbalance, and mitochondrial dysfunction through a comprehensive multi-nutrient approach.

This study observed that both dutasteride and finasteride affected penile morphology in normotensive and hypertensive rats, with more pronounced changes in hypertensive animals, especially when treated with dutasteride.

This study examined connections between bioelements like Zn, Cu, and Mn in serum and bone tissue and hormone concentrations in men with and without erectile dysfunction, highlighting potential relationships that may help explain ED's etiology.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.

This document outlines recommendations from an international panel on testosterone therapy for aging men with late-onset hypogonadism, emphasizing the need for careful assessment and monitoring due to limited long-term safety data.

This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

This article reviews considerations and guidelines for testosterone therapy in older men with low testosterone levels but does not provide new clinical results, emphasizing the need for ongoing evaluation and careful management, particularly regarding risks related to prostate and cardiovascular health.

This study found that oral finasteride 1 mg/day promotes hair growth and prevents further hair loss in a significant proportion of men with male pattern hair loss over two years.

This review analyzes how the pharmaceutical industry's emphasis on lifestyle drugs and marketing practices leads to the integration of pharmaceuticals into everyday life, with a domestic focus and view of drugs as quick solutions.

5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.

This study highlights that adverse effects from finasteride may persist in men after discontinuation, indicating a potential "post-finasteride syndrome.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This study found that patients with post-finasteride syndrome exhibited major depressive disorder, severe erectile dysfunction, and neuropathy, alongside altered neuroactive steroid levels in cerebrospinal fluid.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

In this study, the authors concluded that COVID-19 may not cause direct long-term harm to testicular function, but temporary indirect effects could occur, suggesting a possible delay in pursuing parenthood post-recovery.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

In this case study, clomiphene citrate therapy restored hormonal balance and improved symptoms in a young male runner with hypogonadotropic hypogonadism related to endurance exercise.

This article examines the evidence regarding finasteride's sexual side effects and offers recommendations for patient counseling but reports no new clinical findings.

This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.